Tallac Therapeutics, Inc. — Form D/A
Tallac Therapeutics, Inc. of BURLINGAME, CA, a company, filed a Form D amendment with the SEC on 2021-07-22. The offering totals $61.6M, of which $61.6M was reported sold. Industry: Other Health Care.
Offering
- Filed: 2021-07-22
- Form: D/A
- Accession: 0001819027-21-000003
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $61.6M
- Amount sold: $61.6M
- Investors: 12
- Date of first sale: 2020-06-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-371827
Issuer
- Name: Tallac Therapeutics, Inc.
- CIK: 0001819027
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 866 MALCOLM ROAD, SUITE 100, BURLINGAME, CA, 94010
- Phone: (650) 681-0458
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Christine Brennan | Director | Watertown, MA |
| MICHAEL CARUSI | Director | San Clemente, CA |
| Isaac Cheng | Director | Portland, ME |
| Ran Geng | Director | Burlingame, CA |
| Corey Goodman | Director | Cambridge, MA |
| Jaume Pons | Director | Burlingame, CA |
| Hong Wan | Director | Burlingame, CA |
| Hong Wan | Executive Officer | Burlingame, CA |
Other filings by this issuer (1)
More